thiophenes has been researched along with canagliflozin in 137 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 135 (98.54) | 24.3611 |
| 2020's | 2 (1.46) | 2.80 |
| Authors | Studies |
|---|---|
| Hongu, M; Kawanishi, E; Kimata, H; Koga, Y; Nakayama, K; Nomura, S; Sakamaki, S; Sakamoto, T; Tsuda-Tsukimoto, M; Ueta, K; Yamamoto, Y | 1 |
| Chien, S; Demarest, K; Devineni, D; Ghosh, A; Polidori, D; Rothenberg, P; Sha, S; Shalayda, K; Wexler, D | 1 |
| Cassader, M; Gambino, R; Musso, G; Pagano, G | 1 |
| Heger, M | 1 |
| Basile, J | 1 |
| Devineni, D; Hompesch, M; Morrow, L; Murphy, J; Schwartz, S; Skee, D; Vandebosch, A; Ways, K | 1 |
| Arakawa, K; Conway, B; Conway, J; Demarest, K; Du, F; Kuriyama, C; Liang, Y; Liu, Y; Martin, T; Matsushita, Y; Polidori, D; Ueta, K; Ways, K; Xu, J | 1 |
| Aggarwal, N; Arbit, D; Canovatchel, W; Capuano, G; Polidori, D; Rosenstock, J; Usiskin, K; Zhao, Y | 1 |
| Simonyi, G | 1 |
| Capuano, G; Nicolle, LE; Usiskin, K; Ways, K | 1 |
| Nyirjesy, P; Usiskin, K; Ways, K; Zhao, Y | 1 |
| Komala, MG; Mather, A; Panchapakesan, U; Pollock, C | 1 |
| Alba, M; Canovatchel, W; Cefalu, WT; Kim, KA; Meininger, G; Stenlöf, K; Tong, C; Usiskin, K | 1 |
| Forst, T; Rosak, C | 1 |
| Kolanczyk, DM; Nisly, SA; Walton, AM | 1 |
| Ciaraldi, TP; Farrell, K; Ghosh, A; Henry, RR; Mudaliar, S; Polidori, D; Rothenberg, P; Sha, S; Vaccaro, N | 1 |
| Bakris, G; Cariou, B; David-Neto, E; Figueroa, K; Meininger, G; Usiskin, K; Wajs, E; Xi, L; Yale, JF; Yue, D | 1 |
| Canovatchel, W; Fu, M; Gross, JL; Guarisco, M; Kawaguchi, M; Meininger, G; Rosenstock, J; Schernthaner, G; Yee, J | 1 |
| Ghosh, A; Heise, T; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S | 1 |
| Davis, SN; Lamos, EM; Younk, LM | 1 |
| Traynor, K | 1 |
| Curtin, CR; Devineni, D; Gutierrez, MJ; Murphy, J; Polidori, D; Rothenberg, PL; Rusch, S | 1 |
| Bode, B; Fung, A; Stenlöf, K; Sullivan, D; Usiskin, K | 1 |
| Bloomgarden, Z | 1 |
| Elkinson, S; Scott, LJ | 1 |
| Lange-Chenier, H | 1 |
| Harris, KB; Riser Taylor, S | 1 |
| Freeman, JS | 1 |
| Johnson, MS | 1 |
| Inagaki, N; Kondo, K; Kuki, H; Maruyama, N; Susuta, Y; Yoshinari, T | 1 |
| Gebel, E | 1 |
| Babu, A | 1 |
| Hongu, M; Kawanishi, E; Kimata, H; Koga, Y; Kuriyama, C; Matsushita, Y; Nakayama, K; Nomura, S; Sakamaki, S; Sakamoto, T; Tsuda-Tsukimoto, M; Ueta, K; Yamamoto, Y | 1 |
| Arias, P; Balis, DA; Canovatchel, W; Cefalu, WT; Leiter, LA; Meininger, G; Niskanen, L; Xie, J; Yoon, KH | 1 |
| Diamant, M; Morsink, LM | 1 |
| de Zeeuw, D; Desai, M; Fulcher, G; Jiang, J; Mahaffey, KW; Matthews, D; Meininger, G; Neal, B; Perkovic, V; Shaw, W; Stein, P; Vercruysse, F | 1 |
| Jungemann, S; Van Gilder, D | 1 |
| Andrianesis, V; Doupis, J | 1 |
| Hernandez, GT; Said, S | 1 |
| Canovatchel, W; Davidson, J; Januszewicz, A; Lavalle-González, FJ; Meininger, G; Qiu, R; Tong, C | 1 |
| Bagga, P; Biswas, D; Kamal, MA; Rizvi, SM; Shaikh, S; Shakil, S | 1 |
| Alba, M; Canovatchel, W; Cefalu, WT; Edwards, R; Jodar, E; Kim, KA; Meininger, G; Stenlöf, K; Tong, C | 1 |
| Black, S; Canovatchel, W; Charpentier, G; González-Gálvez, G; Hollander, P; Law, G; Mathieu, C; Meininger, G; Usiskin, K; Vercruysse, F; Wilding, JP | 1 |
| Akhtar, N | 1 |
| Vouyiouklis, M | 1 |
| Bays, HE; Canovatchel, W; Law, G; Weinstein, R | 1 |
| Gilbert, RE | 1 |
| Baker, WL; Nigro, SC; Pheng, M; Riche, DM | 1 |
| Dietrich, E; Powell, J; Taylor, JR | 1 |
| Balis, DA; Meininger, G; Tong, C | 1 |
| Grassos, CE; Kallikazaros, IE; Katsi, VK; Lekakis, JP; Makris, TK; Michalakeas, CA; Stefanadis, CI; Tousoulis, D; Vamvakou, GD | 1 |
| Scheen, AJ | 4 |
| Capuano, G; Fung, A; Nicolle, LE; Usiskin, K | 1 |
| Fukazawa, M; Hiramatsu, M; Honda, K; Kawabe, Y; Matsumoto, M; Suzuki, M; Suzuki, Y | 1 |
| García, SD | 1 |
| Mauricio, D | 1 |
| Mikhail, N | 2 |
| Seufert, J | 2 |
| Matthaei, S | 1 |
| Schnell, O | 1 |
| Bailey, RA; Blonde, L; Damaraju, CV; Martin, SC; Meininger, GE; Rupnow, MF | 1 |
| Capuano, G; Fung, A; Mayer, C; Nyirjesy, P; Sobel, JD; Usiskin, K; Ways, K | 1 |
| Forst, T; Goldenberg, R; Guthrie, R; Meininger, G; Stein, P; Vijapurkar, U; Yee, J | 1 |
| Chen, J; Cuyckens, F; Devineni, D; Evans, DC; Johnson, MD; Kalamaridis, D; Kelley, MF; Lim, HK; Lin, R; Mamidi, RN; Scheers, E; Sha, S; Silva, J | 1 |
| Ferrannini, E; Mari, A; Polidori, D | 1 |
| Bakris, GL; Oliva, RV | 1 |
| Kumar, M; Kumar, R; Mahapatra, MK; Malla, P | 1 |
| Condren, AB; Donahue, EP; Farmer, TD; Healey, EC; Kim, K; McCoy, GA; O'Brien, TP; Printz, RL; Shiota, M; Ueta, K | 1 |
| Devineni, D; Polidori, D; Rusch, S; Vaccaro, N; Wajs, E | 1 |
| Bode, B; Desai, M; Fung, A; Harris, S; Mayer, C; Meininger, G; Shaw, W; Sinclair, A; Usiskin, K; Vijapurkar, U | 1 |
| Edwards, R; Kline, I; Usiskin, K; Weir, MR; Xie, J | 1 |
| Plosker, GL | 1 |
| Baggett, S; Elmore, LK; Kyle, JA; Skelley, JW | 1 |
| Guthrie, R; Slee, A; Traina, S | 1 |
| Fung, A; Kline, I; Mayer, C; Meininger, G; Usiskin, K | 1 |
| Farrell, K; Heise, T; Natarajan, J; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S; Sica, D; Wang, SS | 1 |
| Chung, SH; Kim, GW | 1 |
| Bakris, G; Cariou, B; David-Neto, E; Figueroa, K; Jiang, J; Law, G; Meininger, G; Nieto, J; Usiskin, K; Wajs, E; Yale, JF; Yue, D | 1 |
| Inagaki, N; Kondo, K; Kuki, H; Susuta, Y; Takahashi, N; Yoshinari, T | 1 |
| Dou, J; Lu, J; Zhang, Q | 1 |
| Bakris, G; Davies, M; de Zeeuw, D; Kline, I; Mayer, C; Meininger, G; Perkovic, V; Usiskin, K; Vijapurkar, U; Woo, V; Yamout, H | 1 |
| Artis, E; Berg, JK; Devineni, D; Morrow, L; Polidori, D; Rusch, S; Stein, P; Vaccaro, N | 1 |
| Huang, YL; Lai, D; Shen, HP; Yang, XP; Zhong, XY | 1 |
| Bryant, S; De Jonghe, S; Feyen, B; Johnson, MD; Kelley, MF; Lammens, G; Louden, C; Ma, JY; Mamidi, RN; Moesen, E; Proctor, J; Snook, S; Vinken, P; Ways, K | 1 |
| Arnolds, S; Demarest, K; Devineni, D; Ghosh, A; Hompesch, M; Morrow, L; Polidori, D; Rothenberg, P; Sha, S; Spitzer, H | 1 |
| Dieu Van, NK; Han, P; Ji, L; Liu, Y; Meininger, G; Qiu, R; Vijapurkar, U; Yang, G | 1 |
| Furihata, K; Inagaki, N; Ishii, M; Kondo, K; Kuki, H; Sakai, M; Yoshinari, T | 1 |
| Arias, P; Balis, DA; Canovatchel, W; Langslet, G; Leiter, LA; Meininger, G; Millington, D; Vercruysse, F; Xie, J; Yoon, KH | 1 |
| Arakawa, K; Hikida, K; Kakimoto, T; Kimata, H; Kuriyama, C; Lee, SP; Matsushita, Y; Nakayama, K; Qi, J; Saito, A; Shiotani, M; Taniuchi, N; Ueta, K; Watanabe, Y; Xu, JZ | 1 |
| Christensen, M; Gluud, LL; Knop, FK; Storgaard, H; Vilsbøll, T | 1 |
| Nauck, MA | 1 |
| Brunton, S; Reid, TS | 1 |
| De Jonghe, S; Feyen, B; Geys, H; Johnson, MD; Mamidi, RN; Marien, D; Proctor, J; Vinken, P; Wynant, I | 1 |
| Lajara, R | 1 |
| Fung, A; Gilbert, RE; Januszewicz, A; Kline, I; Meininger, G; Vijapurkar, U; Weir, MR | 1 |
| Boyle, LD; Wilding, JP | 1 |
| Vallon, V | 1 |
| Bernard, A; Devineni, D; Mamidi, RN; Manitpisitkul, P; Rothenberg, P; Sha, S; Skee, D; Stieltjes, H; Tian, H; Vaccaro, N; Weiner, S | 1 |
| Buysman, EK; Chow, W; Henk, HJ; Rupnow, MF | 1 |
| Ariyawansa, J; Curtin, C; Devineni, D; Di Prospero, NA; Mamidi, RN; Murphy, J; Rothenberg, P; Stieltjes, H; Vaccaro, N; Wajs, E; Wang, SS; Weiner, S | 1 |
| Davidson, JA; Kuritzky, L | 1 |
| Farrell, K; Ghosh, A; Natarajan, J; Pinheiro, J; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S; Vaccaro, N | 1 |
| Kinoshita, S; Kondo, K | 1 |
| Alba, M; Capuano, G; de Zeeuw, D; Desai, M; Fulcher, G; Jiang, J; Mahaffey, KW; Matthews, D; Meininger, G; Neal, B; Perkovic, V; Shaw, W; Vercruysse, F; Ways, K | 1 |
| Cherney, DZ; Škrtić, M | 1 |
| Al-Rashood, KA; Asiri, YA; Ezzeldin, E; Iqbal, M; Rezk, NL | 1 |
| Bode, B; Fung, A; Harris, S; Meininger, G; Stenlöf, K; Sullivan, D; Usiskin, K | 1 |
| Devineni, D; Polidori, D; Stieltjes, H; Vaccaro, N; Wajs, E | 1 |
| Devineni, D; Murphy, J; Stieltjes, H; Wajs, E; Wang, SS | 1 |
| Mehr, SR; Zimmerman, MP | 1 |
| Miller, SA; Powell, J; Taylor, JR | 1 |
| Bakris, GL; Majewski, C | 1 |
| Bailey, RA; Blonde, L; Meininger, GE; Rupnow, MF; Vijapurkar, U | 1 |
| Rupprecht, H | 1 |
| Bailey, RA; Blonde, L; Meininger, G; Rupnow, MF; Vijapurkar, U | 1 |
| Dutta, D; Kalra, S | 1 |
| Curtin, CR; Devineni, D; Murphy, J; Polidori, D; Stieltjes, H; Wajs, E; Wang, SS | 1 |
| Chen, X; Curtin, CR; Devineni, D; Hu, P; Polidori, D; Sha, S; Stieltjes, H; Vaccaro, N; Weiner, S | 1 |
| Imamura, M; Kurosaki, E; Tahara, A; Takasu, T; Yokono, M | 1 |
| Bailey, RA; Blonde, L; Meininger, G; Patel, CA; Vijapurkar, U | 1 |
| Del Gobbo, LC; Li, Y; Song, Y; Tang, H; Zhai, S; Zhang, J; Zhang, X | 1 |
| Kutoh, E; Murayama, T; Takizawa, Y; Wada, A | 1 |
| Gao, HK; Kengne, AP; Mazidi, M; Rezaie, P | 1 |
| Aubrey-Bassler, K; Chibrikov, E; Curnew, D; Donnan, JR; Gamble, JM; Grandy, CA; Hache, J; Johnston, K; Marra, CA; Nguyen, H; Swab, M | 1 |
| Ito, K; Kashiwagi, Y; Kimura, H; Nagoshi, T; Oi, Y; Tanaka, TD; Tanaka, Y; Yoshii, A; Yoshimura, M; Yoshino, T | 1 |
| Moradi-Marjaneh, R; Paseban, M; Sahebkar, A | 1 |
| Abe, I; Abe, M; Fujii, H; Kobayashi, K; Kudo, T; Minezaki, M; Mukoubara, S; Ochi, K; Ohe, K; Ohishi, H; Ohnishi, Y; Shinagawa, T; Sugimoto, K; Takashi, Y; Yamao, Y | 1 |
| Mori-Anai, K; Nakada, T; Nakamaru, Y; Saito, R; Takahata, T; Tashima, Y | 1 |
| Inoue, D; Inoue, R; Nangaku, M; Nishi, H | 1 |
54 review(s) available for thiophenes and canagliflozin
| Article | Year |
|---|---|
A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.
Topics: Benzhydryl Compounds; Blood Pressure; Body Mass Index; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transport Proteins; Thiophenes | 2012 |
A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Gluconeogenesis; Glucosides; Homeostasis; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2011 |
[New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors].
Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Phlorhizin; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2012 |
Sodium glucose cotransporter 2 and the diabetic kidney.
Topics: Animals; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
[Glycosuria with SGLT-2 inhibitors--a new treatment approach for type 2 diabetes mellitus].
Topics: Benzhydryl Compounds; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Glipizide; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2012 |
Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.
Topics: Animals; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.
Topics: Aged; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucose; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Canaglifozin (Invokana) for type 2 diabetes.
Topics: Animals; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Canagliflozin: first global approval.
Topics: Animals; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Canagliflozin for the treatment of type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Insulin-Secreting Cells; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.
Topics: Animals; Benzhydryl Compounds; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus; Gluconeogenesis; Glucose; Glucosides; Homeostasis; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2013 |
Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus.
Topics: Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; United States | 2013 |
Type 2 diabetes mellitus and Invokana: an FDA approved drug.
Topics: Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Drug Approval; Female; Glucosides; Humans; Hypoglycemic Agents; India; Life Style; Male; Obesity; Thiophenes; United States; United States Food and Drug Administration | 2013 |
Canagliflozin: Improving diabetes by making urine sweet.
Topics: Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Disease Progression; Glucosides; Humans; Hypoglycemic Agents; Thiophenes; Treatment Outcome; Urinalysis | 2013 |
Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
Topics: Animals; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Glomerulus; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Uric Acid | 2014 |
Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes.
Topics: Animals; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Canagliflozin: a novel treatment option for type 2 diabetes.
Topics: Animals; Biomarkers; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Drug Design; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2013 |
Canagliflozin: a new hope in the antidiabetic armamentarium.
Topics: Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Interactions; Glucosides; Hepatic Insufficiency; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
[Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus].
Topics: Adsorption; Animals; Benzhydryl Compounds; Biological Transport, Active; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drugs, Investigational; Glucose; Glucosides; Glycosides; Glycosuria; Glycosuria, Renal; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Malus; Phlorhizin; Phytotherapy; Plant Bark; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2013 |
[SGLT-2 inhibition with canagliflozin: a new option for the treatment of type 2 diabetes].
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney; Kidney Concentrating Ability; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
[Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus].
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison beween canagliflozin and glimepiride].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Male; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiophenes | 2014 |
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and sitagliptin].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiophenes; Triazoles; Young Adult | 2014 |
Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Glucosides; Humans; Hypoglycemic Agents; Kidney; Renal Reabsorption; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Glycemic Index; Glycosuria; Humans; Hypoglycemic Agents; Male; Severity of Illness Index; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2014 |
Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR).
Topics: Adult; Aged; Biomarkers; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Electrolytes; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Water-Electrolyte Imbalance | 2014 |
Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Molecular Structure; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes.
Topics: Aged; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Glucosides; Glycated Hemoglobin; Humans; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Clinical implication of SGLT2 inhibitors in type 2 diabetes.
Topics: Administration, Oral; Benzhydryl Compounds; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Kidney; Molecular Structure; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes | 2014 |
Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Insulin Resistance; Randomized Controlled Trials as Topic; Renal Elimination; Sodium-Glucose Transporter 2 Inhibitors; Systematic Reviews as Topic; Thiophenes; Treatment Outcome | 2014 |
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Kidney; Lipids; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Practice Guidelines as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes.
Topics: Animals; Biomarkers; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2014 |
The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Homeostasis; Humans; Hypoglycemic Agents; Kidney; Renal Reabsorption; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Invokamet and Xigduo XR: two new combinations for type 2 diabetes.
Topics: Benzhydryl Compounds; Canagliflozin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transport Proteins; Thiophenes; United States | 2014 |
Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Renal Reabsorption; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sodium, Dietary; Thiophenes | 2015 |
Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.
Topics: Benzhydryl Compounds; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2015 |
Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
Topics: Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine; Glucosides; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Weight Loss | 2015 |
[The role of SGLT-2 inhibitors in the treatment of type 2 diabetes].
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials.
Topics: Blood Pressure; Body Mass Index; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiophenes; Triazoles | 2015 |
[Canagliflozin (Invokana): kidney SGLT2 cotransporter inhibitor for treating type 2 diabetes].
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Magnesium; Male; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Young Adult | 2017 |
Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
Topics: Acute Kidney Injury; Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Diabetic Ketoacidosis; Fractures, Bone; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Urinary Tract Infections | 2019 |
Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes.
Topics: Benzhydryl Compounds; Biological Products; Canagliflozin; Diabetes Mellitus; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
47 trial(s) available for thiophenes and canagliflozin
| Article | Year |
|---|---|
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.
Topics: Adolescent; Adult; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2011 |
Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
Topics: Adolescent; Adult; Aged; Blood Glucose; Canagliflozin; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Thiophenes; Time Factors; Treatment Outcome; Young Adult | 2012 |
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Weight Loss; Young Adult | 2012 |
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
Topics: Bacteriuria; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles; Urinary Tract Infections | 2012 |
Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Topics: Antifungal Agents; Blood Glucose; Canagliflozin; Candida; Candidiasis, Vulvovaginal; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles; Vagina | 2012 |
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Exercise; Fasting; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Postprandial Period; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triglycerides; Weight Loss | 2013 |
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.
Topics: Acetaminophen; Adolescent; Adult; Blood Glucose; Canagliflozin; Cross-Over Studies; Depression, Chemical; Gastric Emptying; Glucose; Glucosides; Glycosuria; Humans; Insulin; Intestinal Absorption; Male; Placebos; Postprandial Period; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
Topics: Aged; Biomarkers; Blood Glucose; Body Weight; Canagliflozin; Comorbidity; Diabetes Mellitus, Type 2; Disease Progression; Diuresis; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Urinary Tract Infections | 2013 |
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Triazoles | 2013 |
Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.
Topics: Blood Glucose; Body Mass Index; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Glycosuria; Humans; Hyperglycemia; Hypoglycemic Agents; Kidney; Kidney Function Tests; Male; Membrane Transport Modulators; Middle Aged; Overweight; Postprandial Period; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
Topics: Adult; Area Under Curve; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucose; Glucosides; Glucuronides; Half-Life; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
Topics: Age Factors; Aged; Aged, 80 and over; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Safety; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Thiophenes; Treatment Outcome; Young Adult | 2013 |
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Young Adult | 2013 |
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
Topics: Aged; Biomarkers; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Electrocardiography; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Topics: Adolescent; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles | 2013 |
Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Exercise; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triazoles; Triglycerides; Weight Loss | 2014 |
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Lipid Metabolism; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Weight Loss; Young Adult | 2013 |
Canagliflozin: effects in overweight and obese subjects without diabetes mellitus.
Topics: Adult; Anti-Obesity Agents; Blood Pressure; Body Mass Index; Body Weight; Canagliflozin; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucose; Glucosides; Humans; Male; Middle Aged; Obesity; Overweight; Sodium-Glucose Transport Proteins; Thiophenes; Treatment Outcome | 2014 |
Effect of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol.
Topics: Blood Glucose; Canagliflozin; Deoxyglucose; Diabetes Mellitus, Type 2; Double-Blind Method; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Prognosis; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Recurrence; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Urinary Tract Infections; Young Adult | 2014 |
Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
Topics: Aged; Blood Pressure; Body Mass Index; Canagliflozin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Quality Indicators, Health Care; Racial Groups; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles | 2014 |
Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.
Topics: Aged; Canagliflozin; Diabetes Mellitus, Type 2; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Mycoses; Thiophenes | 2014 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Topics: Blood Glucose; Blood Pressure; Canagliflozin; Candidiasis; Diabetes Mellitus, Type 2; Diuretics, Osmotic; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Thiophenes; Treatment Outcome; Triazoles; Weight Loss | 2014 |
Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.
Topics: Administration, Oral; Adult; Animals; Bile; Canagliflozin; Carbon Radioisotopes; Dogs; Feces; Female; Glucosides; Glucuronides; Humans; Hypoglycemic Agents; Magnetic Resonance Spectroscopy; Male; Mice; Middle Aged; Rats; Rats, Sprague-Dawley; Species Specificity; Thiophenes; Tissue Distribution; Young Adult | 2014 |
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Insulin-Secreting Cells; Least-Squares Analysis; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiophenes; Time Factors; Triazoles | 2014 |
Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
Topics: Adolescent; Adult; Blood; Canagliflozin; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Healthy Volunteers; Humans; Hydrochlorothiazide; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Urine; Young Adult | 2014 |
The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes.
Topics: Adult; Age Factors; Aged; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Health Behavior; Humans; Hypoglycemic Agents; Male; Middle Aged; Personal Satisfaction; Pyrazines; Quality of Life; Self Efficacy; Sex Factors; Sexual Behavior; Sitagliptin Phosphate; Thiophenes; Triazoles; Weight Loss | 2014 |
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Kidney; Male; Metformin; Middle Aged; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Water-Electrolyte Balance; Weight Loss | 2014 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2014 |
Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study.
Topics: Aged; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise Therapy; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Ketone Bodies; Lipids; Male; Middle Aged; Thiophenes; Treatment Outcome; Weight Loss | 2014 |
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
Topics: Blood Glucose; Canagliflozin; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucose; Glucosides; Humans; Kidney; Male; Metformin; Middle Aged; Postprandial Period; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Insulin; Kidney; Male; Middle Aged; Thiophenes | 2014 |
Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
Topics: Aged; Canagliflozin; China; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Malaysia; Male; Membrane Transport Modulators; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Vietnam | 2015 |
Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.
Topics: Adult; Aged; Area Under Curve; Asian People; Canagliflozin; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Renal Insufficiency; Thiophenes | 2014 |
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
Topics: Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Time Factors; Treatment Outcome; Weight Loss | 2015 |
Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
Topics: Adult; Anticoagulants; Area Under Curve; Blood Coagulation; Canagliflozin; Cardiotonic Agents; Contraceptives, Oral, Combined; Cross-Over Studies; Digoxin; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Drug Interactions; Ethinyl Estradiol; Female; Glucosides; Half-Life; Healthy Volunteers; Humans; Hypoglycemic Agents; International Normalized Ratio; Levonorgestrel; Male; Metabolic Clearance Rate; Middle Aged; Polypharmacy; Risk Assessment; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Warfarin; Young Adult | 2015 |
Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
Topics: Adult; Canagliflozin; Cyclosporine; Drug Interactions; Female; Glucosides; Humans; Male; Probenecid; Rifampin; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Canagliflozin; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Postprandial Period; Thiophenes | 2015 |
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Hypovolemia; Insulin; Male; Middle Aged; Mycoses; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2015 |
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diuresis; Double-Blind Method; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Mycoses; Osmolar Concentration; Thiophenes; Urinary Tract Infections | 2015 |
Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
Topics: Adult; Canagliflozin; Dose-Response Relationship, Drug; Female; Glucosides; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Canagliflozin; Cross-Over Studies; Drug Combinations; Fasting; Female; Food-Drug Interactions; Glucosides; Half-Life; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Metformin; Middle Aged; Postprandial Period; Tablets; Therapeutic Equivalency; Thiophenes; Young Adult | 2015 |
Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials.
Topics: Blood Pressure; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles | 2014 |
Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
Topics: Administration, Oral; Adult; Area Under Curve; Blood Glucose; Canagliflozin; Cross-Over Studies; Drug Administration Schedule; Drug Monitoring; Female; Glucosides; Half-Life; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Models, Biological; Risk Assessment; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2015 |
Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects.
Topics: Adolescent; Adult; Asian People; Blood Glucose; Canagliflozin; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Glycosuria; Healthy Volunteers; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2015 |
Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Humans; Intestinal Absorption; Kidney; Male; Middle Aged; Models, Biological; Postprandial Period; Pyrazoles; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines; Thiophenes; Young Adult | 2020 |
36 other study(ies) available for thiophenes and canagliflozin
| Article | Year |
|---|---|
Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Topics: Animals; Biological Availability; Canagliflozin; Carbonates; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Male; Mice; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Stereoisomerism; Structure-Activity Relationship; Thiophenes | 2010 |
New diabetes drugs go beyond insulin to flush out excess sugar.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Thiophenes | 2011 |
Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.
Topics: Animals; Blood Glucose; Body Weight; Canagliflozin; Cells, Cultured; CHO Cells; Cricetinae; Diabetes Mellitus, Experimental; Glucose Tolerance Test; Glucosides; Humans; Hyperglycemia; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Muscle, Skeletal; Rats; Rats, Zucker; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Gain | 2012 |
Canagliflozin approved for type 2 diabetes.
Topics: Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; Thiophenes; United States; United States Food and Drug Administration | 2013 |
Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycosides; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
US approves "new class" of diabetes drug, under review in Canada.
Topics: Canada; Canagliflozin; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; Thiophenes; United States | 2013 |
The top 10 drug trends right now.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Azepines; Biphenyl Compounds; Canagliflozin; Cholesterol Ester Transfer Proteins; Dimethyl Fumarate; Drug Approval; Forecasting; Fumarates; gamma-Cyclodextrins; Glucosides; Humans; Lactones; Maytansine; Pyridines; Sofosbuvir; Sugammadex; Thiophenes; Trastuzumab; Triazoles; United States; United States Food and Drug Administration; Uridine Monophosphate | 2013 |
A novel approach.
Topics: Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors.
Topics: Animals; Blood Glucose; Canagliflozin; Cell Line; CHO Cells; Cricetinae; Cricetulus; Diet, High-Fat; Glucosides; Half-Life; Humans; Hypoglycemic Agents; Male; Mice; Monosaccharides; Protein Binding; Pyridines; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
SGLT2 inhibitors for diabetes: turning symptoms into therapy.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes | 2013 |
Treating type 2 diabetes with canagliflozin.
Topics: Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2013 |
Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study.
Topics: Alzheimer Disease; Animals; Canagliflozin; Cholinesterase Inhibitors; Computer Simulation; Databases, Protein; Diabetes Mellitus, Type 2; Glucosides; Humans; Models, Molecular; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans.
Topics: Animals; Benzhydryl Compounds; Canagliflozin; Candida albicans; Candidiasis; Disease Progression; Female; Glucosides; Glycosuria; Kidney; Mice; Mice, Inbred C57BL; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Urinary Tract Infections | 2014 |
[Introduction].
Topics: Benzhydryl Compounds; Biological Transport, Active; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Safety of canagliflozin in patients with type 2 diabetes.
Topics: Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hyperkalemia; Hypoglycemic Agents; Lipids; Male; Thiophenes; Urinary Tract Infections; Urination | 2014 |
Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity.
Topics: Animals; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Eating; Glucagon; Glucokinase; Glucose; Glucose Clamp Technique; Glucosides; Hyperglycemia; Hyperinsulinism; Immunohistochemistry; Liver; Male; Obesity; Organ Size; Oxygen Consumption; Rats; Rats, Zucker; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Meta-Analysis as Topic; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Thiophenes; Young Adult | 2014 |
Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
Topics: Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Kidney Function Tests; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic; Severity of Illness Index; Sex Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Severity of Illness Index; Thiophenes; Treatment Outcome | 2014 |
Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin.
Topics: Animals; Canagliflozin; Carbohydrate Metabolism, Inborn Errors; Carcinogenesis; Cell Adhesion Molecules; Cell Proliferation; Glucosides; Immunohistochemistry; Kidney; Malabsorption Syndromes; Male; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in zucker diabetic Fatty rats.
Topics: Animals; Blood Glucose; Canagliflozin; Diabetes Mellitus, Experimental; Dogs; Glucose; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Kidney; Mice; Rats; Rats, Zucker; Sodium-Glucose Transporter 2; Thiophenes | 2014 |
Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin.
Topics: Adrenal Gland Neoplasms; Animals; Canagliflozin; Carcinogenesis; Carcinogenicity Tests; Dose-Response Relationship, Drug; Glucosides; Kidney Neoplasms; Kidney Tubules; Leydig Cell Tumor; Male; Pheochromocytoma; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Structure-Activity Relationship; Testicular Neoplasms; Thiophenes | 2014 |
Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.
Topics: Aged; Blood Pressure; Blood Pressure Determination; Canagliflozin; Diabetes Mellitus, Type 2; Diuresis; Female; Glucosides; Humans; Hypertension; Male; Middle Aged; Sodium-Glucose Transporter 2; Thiophenes | 2014 |
Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting.
Topics: Adult; Aged; Blood Glucose; Canagliflozin; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Medicare Part C; Middle Aged; Retrospective Studies; Thiophenes; Treatment Outcome; United States | 2015 |
Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers.
Topics: Adult; Asian People; Canagliflozin; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Evaluation; Drug Interactions; Glucosides; Healthy Volunteers; Humans; Male; Pyrazoles; Thiazolidines; Thiophenes; Young Adult | 2015 |
Rapid determination of canagliflozin in rat plasma by UHPLC-MS/MS using negative ionization mode to avoid adduct-ions formation.
Topics: Acetonitriles; Administration, Oral; Animals; Canagliflozin; Chromatography, High Pressure Liquid; Drug Stability; Glucosides; Hypoglycemic Agents; Indoles; Limit of Detection; Male; Phenylcarbamates; Rats; Rats, Wistar; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Tandem Mass Spectrometry; Thiophenes; Time Factors; Tosyl Compounds; Water | 2015 |
What is the place of new SGLT-2 inhibitors in therapy and on the formulary?
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Formularies as Topic; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Canagliflozin (Invokana). A "me-too" of the dangerous dapagliflozin.
Topics: Benzhydryl Compounds; Biomarkers; Canagliflozin; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2015 |
Sodium glucose transporter 2 (sglt2) inhibitors: Current status in clinical practice.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Mice, Inbred ICR; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes; Tissue Distribution | 2016 |
A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
Topics: Aged; Blood Glucose; Blood Pressure Determination; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality Indicators, Health Care; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiophenes; Treatment Outcome | 2016 |
Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy.
Topics: Atherosclerosis; Blood Glucose; Body Mass Index; Canagliflozin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Thiophenes; Triglycerides | 2017 |
Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diet, High-Fat; Disease Models, Animal; Glucose Transporter Type 4; Glucosides; Insulin Resistance; Isolated Heart Preparation; Male; Mice, Inbred C57BL; Myocardial Reperfusion Injury; Myocytes, Cardiac; Obesity; Phlorhizin; Signal Transduction; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiologists; Cardiovascular System; Data Analysis; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Japan; Kidney; Male; Prescriptions; Regression Analysis; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes | 2021 |